Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Infectious Diseases and TherapyOpen Access

Prevalence of Macrolide-Resistant Mycoplasma pneumoniae Infections After the COVID-19 Pandemic in Southern Italy, 2023–2025

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFrancesca CentroneMAMarisa AccogliRMRaffaella Melilli

Discussion

Loading...

Member takes

Overview

Observational analysis reveals 7.5% macrolide resistance in Mycoplasma pneumoniae infections in Southern Italy, highlighting the need for ongoing surveillance.

Key Points

  • Macrolide resistance was found in 7.5% of Mycoplasma pneumoniae infections.
  • In May 2025, the prevalence of Mycoplasma pneumoniae peaked at 15.8% among tested samples.
  • A total of 5362 respiratory specimens underwent testing for pathogens using PCR techniques.
  • Continued molecular monitoring is essential to combat the spread of macrolide resistance post-pandemic.

Cite This Study

Centrone et al. (2025) studied this question.

synapsesocial.com/papers/68e7ba40ccde5f1021f64a07https://doi.org/10.1007/s40121-025-01244-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular epidemiology and genomic characterization of post-pandemic macrolide-resistant Mycoplasma pneumoniae in hospitalized children2026
  2. 2Epidemic cycles and post-epidemic decline of Mycoplasma pneumoniae in Italian children: implications for empirical macrolide prescribing.2026
  3. 3Macrolide Resistance of Mycoplasma pneumoniae Among Children in Hangzhou: A 2024–2025 Post-Pandemic Surveillance Study2026
  4. 4Epidemiology and Clinical Impact of Mycoplasma pneumoniae in an Italian Pediatric Center: An Observational Study from 2017 to 20242025
  5. 5P-656. Epidemiology of Mycoplasma pneumoniae Infections after COVID-19 Pandemic2026